Simulation output for your selection:
Type 2 diabetes Romo
Desk job, car, bar
Mechanism: Romo is injected subcutaneously once a month. It binds sclerostin which is a major regulator of bone modelling and thus increases formation and decreases resorption, the perfect combination. However the effect of romosozumab is attenuated after approximately a year. This is probably because the Wnt pathway which controls the reaction of bone cells to loads adapts to the new low sclerostin levels.
Romo an antibody to sclerostin is a particularly interesting drug for people with type 2 diabetes mellitus because their sclerostin levels are high causing low formation and resorption levels.